Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3–5 months follow-up

BACKGROUND: Determining the humoral immunogenicity of tozinameran (BNT162b2) in patients requiring chronic renal replacement therapy, and its impact on COVID-19 morbidity several months after vaccination, may guide risk assessment and changes in vaccination policy. METHODS: In a prospective post-vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben-Dov, Iddo Z., Oster, Yonatan, Tzukert, Keren, Alster, Talia, Bader, Raneem, Israeli, Ruth, Asayag, Haya, Aharon, Michal, Burstein, Ido, Pri-Chen, Hadas, Imam, Ashraf, Abel, Roy, Mor-Yosef Levi, Irit, Khalaileh, Abed, Oiknine-Djian, Esther, Bloch, Aharon, Wolf, Dana G., Dranitzki Elhalel, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731189/
https://www.ncbi.nlm.nih.gov/pubmed/34988942
http://dx.doi.org/10.1007/s40620-021-01210-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731189/
https://www.ncbi.nlm.nih.gov/pubmed/34988942
http://dx.doi.org/10.1007/s40620-021-01210-y

Ejemplares similares